NASDAQ:COGT Cogent Biosciences (COGT) Stock Price, News & Analysis $10.98 +0.08 (+0.73%) (As of 09/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Cogent Biosciences alerts: Email Address About Cogent Biosciences Stock (NASDAQ:COGT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cogent Biosciences alerts:Sign Up Key Stats Today's Range$10.80▼$11.1350-Day Range$8.50▼$11.4852-Week Range$3.67▼$12.14Volume2.59 million shsAverage Volume1.50 million shsMarket Capitalization$1.20 billionP/E RatioN/ADividend YieldN/APrice Target$14.67Consensus RatingModerate Buy Company OverviewCogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Read More… How the US Will Win the Great Lithium Race (Ad)China spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but it processes 70-80%. Now the US is coming over the top by investing $700B+ into domestic supply with the IRA and Bi-partisan Infrastructure Bill.Join GM as an early investor in this company by October 3. Cogent Biosciences Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 46th PercentileCogent Biosciences scored higher than 46% of companies evaluated by MarketBeat, and ranked 655th out of 1,006 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingCogent Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCogent Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Cogent Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cogent Biosciences are expected to grow in the coming year, from ($2.25) to ($2.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cogent Biosciences is -4.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cogent Biosciences is -4.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCogent Biosciences has a P/B Ratio of 4.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cogent Biosciences' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.37% of the outstanding shares of Cogent Biosciences have been sold short.Short Interest Ratio / Days to CoverCogent Biosciences has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.Change versus previous monthShort interest in Cogent Biosciences has recently increased by 0.20%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCogent Biosciences does not currently pay a dividend.Dividend GrowthCogent Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.37% of the outstanding shares of Cogent Biosciences have been sold short.Short Interest Ratio / Days to CoverCogent Biosciences has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.Change versus previous monthShort interest in Cogent Biosciences has recently increased by 0.20%, indicating that investor sentiment is decreasing. News and Social Media2.5 / 5News Sentiment0.59 News SentimentCogent Biosciences has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Cogent Biosciences this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for COGT on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows2 people have added Cogent Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cogent Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.92% of the stock of Cogent Biosciences is held by insiders.Read more about Cogent Biosciences' insider trading history. Receive COGT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cogent Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address COGT Stock News HeadlinesCogent Biosciences (NASDAQ:COGT) Stock Price Up 4.1%September 18 at 2:49 PM | americanbankingnews.comBrokerages Set Cogent Biosciences, Inc. (NASDAQ:COGT) Target Price at $14.67September 14, 2024 | americanbankingnews.comAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt industries worth over $46 trillion. What's even more intriguing?September 20, 2024 | InvestorPlace (Ad)Positive Outlook for Cogent Biosciences Backed by Clinical Trial Progress and Efficient ManagementSeptember 3, 2024 | markets.businessinsider.comHold Rating on Cogent Biosciences Amid Competitive Landscape and Anticipated MilestonesAugust 9, 2024 | markets.businessinsider.comCogent Biosciences Reports Recent Business Highlights and Second Quarter 2024 Financial ResultsAugust 6, 2024 | finance.yahoo.comCogent Biosciences Share Price (COGT.US)August 4, 2024 | lse.co.ukCogent Biosciences: Inflection Year Directly AheadJune 23, 2024 | seekingalpha.comSee More Headlines COGT Stock Analysis - Frequently Asked Questions How have COGT shares performed this year? Cogent Biosciences' stock was trading at $5.88 at the beginning of the year. Since then, COGT shares have increased by 86.7% and is now trading at $10.98. View the best growth stocks for 2024 here. How were Cogent Biosciences' earnings last quarter? Cogent Biosciences, Inc. (NASDAQ:COGT) posted its earnings results on Tuesday, August, 6th. The technology company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.56) by $0.03. Who are Cogent Biosciences' major shareholders? Top institutional shareholders of Cogent Biosciences include Point72 Asset Management L.P. (13.69%), Point72 Asset Management L.P. (9.57%), Deerfield Management Company L.P. Series C (3.42%) and Sofinnova Investments Inc. (2.90%). View institutional ownership trends. How do I buy shares of Cogent Biosciences? Shares of COGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Cogent Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cogent Biosciences investors own include Corbus Pharmaceuticals (CRBP), Visa (V), Viveve Medical (VIVE), Red Violet (RDVT), Freeport-McMoRan (FCX), HP (HPQ) and Nutanix (NTNX). Company Calendar Last Earnings8/06/2024Today9/20/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:COGT CUSIPN/A CIK1460329 Webwww.cogint.com Phone(617) 945-5576FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Stock Price Target$14.67 High Stock Price Target$19.00 Low Stock Price Target$10.00 Potential Upside/Downside+33.6%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-192,410,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-100.92% Return on Assets-57.67% Debt Debt-to-Equity RatioN/A Current Ratio9.25 Quick Ratio9.25 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.30 per share Price / Book4.77Miscellaneous Outstanding Shares109,450,000Free Float89,953,000Market Cap$1.20 billion OptionableOptionable Beta1.70 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report This page (NASDAQ:COGT) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredHow the US Will Win the Great Lithium RaceChina spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but i...DealMaker | SponsoredTrump’s “Tax Free” Retirement StrategySince 1924 — over one hundred years — the US dollar has lost nearly 18x its value. If you're planning on re...Gold Safe Exchange | SponsoredThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt i...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cogent Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.